On May 26, Abivax S.A. rose 9.06% in pre-market trading, trading at $130.46 per share, with trading volume of $1.2215 million.

On the news front, the company disclosed that as of March 31, it held cash, cash equivalents, and short-term investments totaling €491.6 million. Based on current operating assumptions, the company projects its cash runway extending into Q4 of next year, effectively alleviating market concerns over the sustainability of its core drug development programs.

Prior to the earnings release, institutional sentiment had already been tilting bullish, with the majority of sell-side analysts maintaining buy ratings and setting target prices above the prevailing share price. The market had been closely monitoring the impact of the company's financing and royalty arrangements on its expense structure and long-term cash flow trajectory. The strong liquidity position confirmed by the financial disclosure validated these bullish expectations and served as the primary catalyst for the pre-market surge.

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod, is in Phase 3 development for ulcerative colitis and is also being developed for Crohn's disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)